Denosumab and bone loss in uncemented total hip arthroplasty: a secondary 5-year follow-up of a randomized controlled trial
DOI:
https://doi.org/10.2340/17453674.2026.45695Keywords:
Arthroplasty, Bone loss, DXA, Hip, ImplantsAbstract
Background and purpose: Denosumab may preserve periprosthetic bone mineral density (pBMD) around uncemented total hip arthroplasty (THA) components. This exploratory analysis of a previously published randomized controlled trial (RCT) aimed to assess the effects of denosumab on BMD 5 years after treatment cessation.
Methods: 64 non-osteoporotic patients undergoing uncemented THA were enrolled in a randomized, double-blind, placebo-controlled phase-2 trial and received either 2 doses of denosumab or placebo. The primary outcome was pBMD at 12 months, measured by dual-energy X-ray absorptiometry (DEXA). At a mean follow-up of 5.6 years (range 4.3–7.3), 54 patients remained for clinical assessment, DEXA, and plain radiography. The study was registered on ClinicalTrials.gov (NCT01630941).
Results: No differences in pBMD in the acetabular Digas zones or femoral Gruen zones were found between the groups at 5 years. The estimated mean difference in the sum of all zones around the cup was 0.042 g/cm² (95% confidence interval [CI] –0.31 to 0.35; P = 0.8), and for the sum of all Gruen zones –0.06 g/cm² (CI –0.55 to 0.43; P = 0.8). No statistically significant differences were observed in patient-reported outcome measures or the incidence of heterotopic ossification. A gradual decline in pBMD was evident.
Conclusion: At 5 years, the adjusted between-group difference and its 95% confidence interval showed no statistically or clinically relevant effect of denosumab. Whether longer treatment duration or a sequential post-denosumab regimen could influence long-term periprosthetic bone preservation is unknown.
Downloads
References
Cavalli L, Brandi M L. Periprosthetic bone loss: diagnostic and therapeutic approaches. F1000Res 2013; 2: 266. doi: 10.12688/f1000research.2-266.v2. DOI: https://doi.org/10.12688/f1000research.2-266.v1
Sköldenberg O G, Salemyr M O, Bodén H S, Ahl T E, Adolphson P Y. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. J Bone Joint Surg Am 2011; 93: 1857-64. doi: 10.2106/JBJS.J.01646. DOI: https://doi.org/10.2106/JBJS.J.01646
Khatod M, Inacio M C S, Dell R M, Bini S A, Paxton E W, Namba R S. Association of bisphosphonate use and risk of revision after THA: outcomes from a US total joint replacement registry. Clin Orthop Relat Res 2015; 473: 3412-20. doi: 10.1007/s11999-015-4263-4. DOI: https://doi.org/10.1007/s11999-015-4263-4
Namba R S, Inacio M C S, Cheetham T C, Dell R M, Paxton E W, Khatod M X. Lower total knee arthroplasty revision risk associated with bisphosphonate use, even in patients with normal bone density. J Arthroplasty 2016; 31: 537-41. doi: 10.1016/j.arth.2015.09.005. DOI: https://doi.org/10.1016/j.arth.2015.09.005
Wilkinson J M, Eagleton A C, Stockley I, Peel N F A, Hamer A J, Eastell R. Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. J Orthop Res 2005; 23: 1-8. doi: 10.1016/j.orthres.2004.06.004. DOI: https://doi.org/10.1016/j.orthres.2004.06.004
McDonald C L, Lemme N J, Testa E J, Aaron R, Hartnett D A, Cohen E M. Bisphosphonates in total joint arthroplasty: a review of their use and complications. Arthroplasty Today 2022; 14: 133-9. doi: 10.1016/j.artd.2022.02.003. DOI: https://doi.org/10.1016/j.artd.2022.02.003
Aro H T, Nazari-Farsani S, Vuopio M, Löyttyniemi E, Mattila K. Effect of denosumab on femoral periprosthetic BMD and early femoral stem subsidence in postmenopausal women undergoing cementless total hip arthroplasty. JBMR Plus 2019; 3: e10217. doi: 10.1002/jbm4.10217. DOI: https://doi.org/10.1002/jbm4.10217
Aro H T. The potential use of denosumab in patients with arthroplasty. Lancet Rheumatol 2021; 3: e165-6. doi: 10.1016/S2665-9913(20)30447-1. DOI: https://doi.org/10.1016/S2665-9913(20)30447-1
Nyström A, Kiritopoulos D, Ullmark G, Sörensen J, Petrén-Mallmin M, Milbrink J, et al. Denosumab prevents early periprosthetic bone loss after uncemented total hip arthroplasty: results from a randomized placebo-controlled clinical trial. J Bone Miner Res 2020; 35: 239-47. doi: 10.1002/jbmr.3883. DOI: https://doi.org/10.1002/jbmr.3883
Ledin H, Good L, Aspenberg P. Denosumab reduces early migration in total knee replacement: a randomized controlled trial involving 50 patients. Acta Orthop 2017; 88: 255-8. doi: 10.1080/17453674.2017.1300746. DOI: https://doi.org/10.1080/17453674.2017.1300746
Curtis J R, Arora T, Liu Y, Lin T-C, Spangler L, Brunetti V C, et al. Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis. J Bone Miner Res 2024; 39: 826-34. doi: 10.1093/jbmr/zjae079. DOI: https://doi.org/10.1093/jbmr/zjae079
Miller P D, Bolognese M A, Lewiecki E M, McClung M R, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43: 222-9. doi: 10.1016/j.bone.2008.04.007. DOI: https://doi.org/10.1016/j.bone.2008.04.007
Kiritopoulos D, Nyström A, Ullmark G, Sörensen J, Petrén-Mallmin M, Milbrink J, et al. Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial. Acta Orthop 2022; 93: 709-20. doi: 10.2340/17453674.2022.4537. DOI: https://doi.org/10.2340/17453674.2022.4537
Sköld C, Kultima K, Freyhult E, Larsson A, Gordh T, Hailer N P, et al. Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial. Osteoporos Int 2022; 33: 1-8. doi: 10.1007/s00198-022-06423-w. DOI: https://doi.org/10.1007/s00198-022-06423-w
Li X, Han J, Shi X, Bi Z, Liu J. Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos 2023; 18: 37. doi: 10.1007/s11657-023-01227-9. DOI: https://doi.org/10.1007/s11657-023-01227-9
Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 2017; 102: 354-8. doi: 10.1210/jc.2016-3170. DOI: https://doi.org/10.1210/jc.2016-3170
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen E F, Guañabens N, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 2017; 105: 11-17. doi: 10.1016/j.bone.2017.08.003. DOI: https://doi.org/10.1016/j.bone.2017.08.003
Martín-Pérez M, Sánchez-Delgado B, García-Poza P, López-Álvarez S, Martín-Merino E. Multiple vertebral fractures after antiosteoporotic medications discontinuation: a comparative study to evaluate the potential rebound effect of denosumab. Bone 2025; 190: 117325. doi: 10.1016/j.bone.2024.117325. DOI: https://doi.org/10.1016/j.bone.2024.117325
Sølling A S, Harsløf T, Langdahl B. Treatment With zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 2021; 36: 1245-54. doi: 10.1002/jbmr.4305. DOI: https://doi.org/10.1002/jbmr.4305
Kim A S, Girgis C M, McDonald M M. Osteoclast recycling and the rebound phenomenon following denosumab discontinuation. Curr Osteoporos Rep 2022; 20: 505-15. doi: 10.1007/s11914-022-00756-5. DOI: https://doi.org/10.1007/s11914-022-00756-5
Digas G, Kärrholm J, Thanner J. Different loss of BMD using uncemented press-fit and whole polyethylene cups fixed with cement: repeated DXA studies in 96 hips randomized to 3 types of fixation. Acta Orthop 2006; 77: 218-26. doi: 10.1080/17453670610045948. DOI: https://doi.org/10.1080/17453670610045948
Gruen T A, McNeice G M, Amstutz H C. “Modes of failure” of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res 1979; (141): 17-27. DOI: https://doi.org/10.1097/00003086-197906000-00002
Brooker A F, Bowerman J W, Robinson R A, Riley L H J. Ectopic ossification following total hip replacement: incidence and a method of classification. J Bone Joint Surg Am 1973; 55: 1629-32. PMID: 4217797 DOI: https://doi.org/10.2106/00004623-197355080-00006
Kumar S, Wang M, Kim A S, Center J R, McDonald M M, Girgis C M. Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. J Bone Miner Res 2025; 40: 1017-34. doi: 10.1093/jbmr/zjaf037. DOI: https://doi.org/10.1093/jbmr/zjaf037
SAR – Annual report 2023 Swedish Arthroplasty Register. doi: 10.18158/r1HHfziah n.d.
Thillemann T M, Pedersen A B, Mehnert F, Johnsen S P, Søballe K. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone 2010; 46: 946-51. doi: 10.1016/j.bone.2010.01.377. DOI: https://doi.org/10.1016/j.bone.2010.01.377
Herzberg R, Tracey O C, Tahvilian S, Baksh N, Zikria B, Naziri Q. Incidence of heterotopic ossification following total hip arthroplasty by approach: a systematic review. Eur J Orthop Surg Traumatol 2024; 34: 2089-98. doi: 10.1007/s00590-024-03896-9. DOI: https://doi.org/10.1007/s00590-024-03896-9
Purcell K F, Lachiewicz P F. Heterotopic ossification after modern total hip arthroplasty: predisposing factors, prophylaxis, and surgical treatment. J Am Acad Orthop Surg 2023; 31: 490-6. doi: 10.5435/JAAOS-D-22-01070. DOI: https://doi.org/10.5435/JAAOS-D-22-01070
Beckmann J T, Wylie J D, Potter M Q, Maak T G, Greene T H, Aoki S K. Effect of naproxen prophylaxis on heterotopic ossification following hip arthroscopy: a double-blind randomized placebo-controlled trial. J Bone Joint Surg Am 2015; 97: 2032-7. doi: 10.2106/JBJS.N.01156. DOI: https://doi.org/10.2106/JBJS.N.01156
Zhang A-H, Chen X, Zhao Q-X, Wang K-L. A systematic review and meta-analysis of naproxen for prevention heterotopic ossification after hip surgery. Medicine 2019; 98: e14607. doi: 10.1097/MD.0000000000014607. DOI: https://doi.org/10.1097/MD.0000000000014607
Additional Files
Published
How to Cite
License
Copyright (c) 2026 Caroline Sköld, Nils P Hailer, Hans Mallmin
This work is licensed under a Creative Commons Attribution 4.0 International License.
